DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study

Androgen deprivation therapy (ADT) is a key primary treatment for advanced and metastatic prostate cancer and is an important neoadjuvant before radiotherapy. We evaluated 3.0 T dynamic contrast‐enhanced MRI and diffusion‐weighted (DW) MRI in monitoring ADT response. Twenty‐three consecutive patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Magnetic resonance in medicine 2012-03, Vol.67 (3), p.778-785
Hauptverfasser: Barrett, T., Gill, A. B., Kataoka, M. Y., Priest, A. N., Joubert, I., McLean, M. A., Graves, M. J., Stearn, S., Lomas, D. J., Griffiths, J. R., Neal, D., Gnanapragasam, V. J., Sala, E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 785
container_issue 3
container_start_page 778
container_title Magnetic resonance in medicine
container_volume 67
creator Barrett, T.
Gill, A. B.
Kataoka, M. Y.
Priest, A. N.
Joubert, I.
McLean, M. A.
Graves, M. J.
Stearn, S.
Lomas, D. J.
Griffiths, J. R.
Neal, D.
Gnanapragasam, V. J.
Sala, E.
description Androgen deprivation therapy (ADT) is a key primary treatment for advanced and metastatic prostate cancer and is an important neoadjuvant before radiotherapy. We evaluated 3.0 T dynamic contrast‐enhanced MRI and diffusion‐weighted (DW) MRI in monitoring ADT response. Twenty‐three consecutive patients with prostate cancer treated by primary ADT were included. Imaging was performed at baseline and 3 months posttreatment with ADT. After 3 months therapy there was a significant reduction in all dynamic contrast‐enhanced MRI parameters measured in tumor regions of interest (Ktrans, kep, vp, IAUGC‐90); P < 0.001. Areas of normal‐appearing peripheral zone showed no significant change; P = 0.285–0.879. Post‐ADT, there was no significant change in apparent diffusion coefficient values in tumors, whilst apparent diffusion coefficient values significantly decreased in areas of normal‐appearing peripheral zone, from 1.786 × 10−3 mm2/s to 1.561 × 10−3 mm2/s; P = 0.007. As expected the median Prostate‐Specific Antigen (PSA) significantly reduced from 30 ng/mL to 1.5 ng/mL posttreatment, and median prostate volume dropped from 47.6 cm3 to 24.9 cm3; P < 0.001. These results suggest that dynamic contrast‐enhanced MRI and diffusion‐weighted MRI offer different information but that both could prove useful adjuncts to the anatomical information provided by T2‐weighted imaging. dynamic contrast‐enhanced as a marker of angiogenesis may help demonstrate ADT resistance and diffusion‐weighted imaging may be more accurate in determining presence of tumor cell death versus residual tumor. Magn Reson Med, 2012. © 2011 Wiley Periodicals, Inc.
doi_str_mv 10.1002/mrm.23062
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_922497264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>922497264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3622-f864b6432fe5006dad6f7aa32aac324599fe64b4dc40a5e5dd3ae4191c676a3c3</originalsourceid><addsrcrecordid>eNp1kE9P3DAQxa2qFWwXDv0ClW9VDwH_i4N7QwulSGxbIRBHy2tPwG3iBNtbiPjy9XaBW08jjX7vzbyH0AdKDigh7LCP_QHjRLI3aEZrxipWK_EWzUgjSMWpErvofUq_CCFKNWIH7TJGeeGOZujpZHGKTXD45AYvL8-xD7gfgs9D9OEWR0jjEBLgPGygONxCwA7G6P-Y7IeA8x1EM04b2Vg2EHLCDz7f4TEOKZsM2JpgIX7Bx7gFk_zKdz5POOW1m_bQu9Z0Cfaf5xxdfz29WnyrLn6cnS-OLyrLZQnTHkmxkoKzFmpCpDNOto0xnBljORO1Ui0UQjgriKmhdo4bEFRRKxtpuOVz9GnrW566X0PKuvfJQteZAMM6acWYUA0rJ-bo85a05f0UodUlam_ipCnRm6p1qVr_q7qwH59d16se3Cv50m0BDrfAg-9g-r-TXl4uXyyrrcKnDI-vChN_a9nwptY338_0T0LVVSOWmvK_NMaYfA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>922497264</pqid></control><display><type>article</type><title>DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study</title><source>Wiley-Blackwell Open Access Backfiles</source><source>MEDLINE</source><source>Wiley Blackwell Single Titles</source><creator>Barrett, T. ; Gill, A. B. ; Kataoka, M. Y. ; Priest, A. N. ; Joubert, I. ; McLean, M. A. ; Graves, M. J. ; Stearn, S. ; Lomas, D. J. ; Griffiths, J. R. ; Neal, D. ; Gnanapragasam, V. J. ; Sala, E.</creator><creatorcontrib>Barrett, T. ; Gill, A. B. ; Kataoka, M. Y. ; Priest, A. N. ; Joubert, I. ; McLean, M. A. ; Graves, M. J. ; Stearn, S. ; Lomas, D. J. ; Griffiths, J. R. ; Neal, D. ; Gnanapragasam, V. J. ; Sala, E.</creatorcontrib><description>Androgen deprivation therapy (ADT) is a key primary treatment for advanced and metastatic prostate cancer and is an important neoadjuvant before radiotherapy. We evaluated 3.0 T dynamic contrast‐enhanced MRI and diffusion‐weighted (DW) MRI in monitoring ADT response. Twenty‐three consecutive patients with prostate cancer treated by primary ADT were included. Imaging was performed at baseline and 3 months posttreatment with ADT. After 3 months therapy there was a significant reduction in all dynamic contrast‐enhanced MRI parameters measured in tumor regions of interest (Ktrans, kep, vp, IAUGC‐90); P &lt; 0.001. Areas of normal‐appearing peripheral zone showed no significant change; P = 0.285–0.879. Post‐ADT, there was no significant change in apparent diffusion coefficient values in tumors, whilst apparent diffusion coefficient values significantly decreased in areas of normal‐appearing peripheral zone, from 1.786 × 10−3 mm2/s to 1.561 × 10−3 mm2/s; P = 0.007. As expected the median Prostate‐Specific Antigen (PSA) significantly reduced from 30 ng/mL to 1.5 ng/mL posttreatment, and median prostate volume dropped from 47.6 cm3 to 24.9 cm3; P &lt; 0.001. These results suggest that dynamic contrast‐enhanced MRI and diffusion‐weighted MRI offer different information but that both could prove useful adjuncts to the anatomical information provided by T2‐weighted imaging. dynamic contrast‐enhanced as a marker of angiogenesis may help demonstrate ADT resistance and diffusion‐weighted imaging may be more accurate in determining presence of tumor cell death versus residual tumor. Magn Reson Med, 2012. © 2011 Wiley Periodicals, Inc.</description><identifier>ISSN: 0740-3194</identifier><identifier>EISSN: 1522-2594</identifier><identifier>DOI: 10.1002/mrm.23062</identifier><identifier>PMID: 22135228</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>3.0 T ; ADT ; Aged ; Aged, 80 and over ; Androgen Receptor Antagonists - therapeutic use ; Anilides - therapeutic use ; Antineoplastic Agents, Hormonal - therapeutic use ; Contrast Media ; DCE MRI ; Diffusion Magnetic Resonance Imaging - methods ; DW MRI ; Feasibility Studies ; Goserelin - therapeutic use ; Humans ; Imaging, Three-Dimensional ; Male ; Middle Aged ; Nitriles - therapeutic use ; Organometallic Compounds ; prostate cancer ; Prostatic Neoplasms - drug therapy ; Tosyl Compounds - therapeutic use ; Treatment Outcome</subject><ispartof>Magnetic resonance in medicine, 2012-03, Vol.67 (3), p.778-785</ispartof><rights>Copyright © 2011 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3622-f864b6432fe5006dad6f7aa32aac324599fe64b4dc40a5e5dd3ae4191c676a3c3</citedby><cites>FETCH-LOGICAL-c3622-f864b6432fe5006dad6f7aa32aac324599fe64b4dc40a5e5dd3ae4191c676a3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmrm.23062$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmrm.23062$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22135228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barrett, T.</creatorcontrib><creatorcontrib>Gill, A. B.</creatorcontrib><creatorcontrib>Kataoka, M. Y.</creatorcontrib><creatorcontrib>Priest, A. N.</creatorcontrib><creatorcontrib>Joubert, I.</creatorcontrib><creatorcontrib>McLean, M. A.</creatorcontrib><creatorcontrib>Graves, M. J.</creatorcontrib><creatorcontrib>Stearn, S.</creatorcontrib><creatorcontrib>Lomas, D. J.</creatorcontrib><creatorcontrib>Griffiths, J. R.</creatorcontrib><creatorcontrib>Neal, D.</creatorcontrib><creatorcontrib>Gnanapragasam, V. J.</creatorcontrib><creatorcontrib>Sala, E.</creatorcontrib><title>DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study</title><title>Magnetic resonance in medicine</title><addtitle>Magn. Reson. Med</addtitle><description>Androgen deprivation therapy (ADT) is a key primary treatment for advanced and metastatic prostate cancer and is an important neoadjuvant before radiotherapy. We evaluated 3.0 T dynamic contrast‐enhanced MRI and diffusion‐weighted (DW) MRI in monitoring ADT response. Twenty‐three consecutive patients with prostate cancer treated by primary ADT were included. Imaging was performed at baseline and 3 months posttreatment with ADT. After 3 months therapy there was a significant reduction in all dynamic contrast‐enhanced MRI parameters measured in tumor regions of interest (Ktrans, kep, vp, IAUGC‐90); P &lt; 0.001. Areas of normal‐appearing peripheral zone showed no significant change; P = 0.285–0.879. Post‐ADT, there was no significant change in apparent diffusion coefficient values in tumors, whilst apparent diffusion coefficient values significantly decreased in areas of normal‐appearing peripheral zone, from 1.786 × 10−3 mm2/s to 1.561 × 10−3 mm2/s; P = 0.007. As expected the median Prostate‐Specific Antigen (PSA) significantly reduced from 30 ng/mL to 1.5 ng/mL posttreatment, and median prostate volume dropped from 47.6 cm3 to 24.9 cm3; P &lt; 0.001. These results suggest that dynamic contrast‐enhanced MRI and diffusion‐weighted MRI offer different information but that both could prove useful adjuncts to the anatomical information provided by T2‐weighted imaging. dynamic contrast‐enhanced as a marker of angiogenesis may help demonstrate ADT resistance and diffusion‐weighted imaging may be more accurate in determining presence of tumor cell death versus residual tumor. Magn Reson Med, 2012. © 2011 Wiley Periodicals, Inc.</description><subject>3.0 T</subject><subject>ADT</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgen Receptor Antagonists - therapeutic use</subject><subject>Anilides - therapeutic use</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Contrast Media</subject><subject>DCE MRI</subject><subject>Diffusion Magnetic Resonance Imaging - methods</subject><subject>DW MRI</subject><subject>Feasibility Studies</subject><subject>Goserelin - therapeutic use</subject><subject>Humans</subject><subject>Imaging, Three-Dimensional</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nitriles - therapeutic use</subject><subject>Organometallic Compounds</subject><subject>prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Tosyl Compounds - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0740-3194</issn><issn>1522-2594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE9P3DAQxa2qFWwXDv0ClW9VDwH_i4N7QwulSGxbIRBHy2tPwG3iBNtbiPjy9XaBW08jjX7vzbyH0AdKDigh7LCP_QHjRLI3aEZrxipWK_EWzUgjSMWpErvofUq_CCFKNWIH7TJGeeGOZujpZHGKTXD45AYvL8-xD7gfgs9D9OEWR0jjEBLgPGygONxCwA7G6P-Y7IeA8x1EM04b2Vg2EHLCDz7f4TEOKZsM2JpgIX7Bx7gFk_zKdz5POOW1m_bQu9Z0Cfaf5xxdfz29WnyrLn6cnS-OLyrLZQnTHkmxkoKzFmpCpDNOto0xnBljORO1Ui0UQjgriKmhdo4bEFRRKxtpuOVz9GnrW566X0PKuvfJQteZAMM6acWYUA0rJ-bo85a05f0UodUlam_ipCnRm6p1qVr_q7qwH59d16se3Cv50m0BDrfAg-9g-r-TXl4uXyyrrcKnDI-vChN_a9nwptY338_0T0LVVSOWmvK_NMaYfA</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Barrett, T.</creator><creator>Gill, A. B.</creator><creator>Kataoka, M. Y.</creator><creator>Priest, A. N.</creator><creator>Joubert, I.</creator><creator>McLean, M. A.</creator><creator>Graves, M. J.</creator><creator>Stearn, S.</creator><creator>Lomas, D. J.</creator><creator>Griffiths, J. R.</creator><creator>Neal, D.</creator><creator>Gnanapragasam, V. J.</creator><creator>Sala, E.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201203</creationdate><title>DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study</title><author>Barrett, T. ; Gill, A. B. ; Kataoka, M. Y. ; Priest, A. N. ; Joubert, I. ; McLean, M. A. ; Graves, M. J. ; Stearn, S. ; Lomas, D. J. ; Griffiths, J. R. ; Neal, D. ; Gnanapragasam, V. J. ; Sala, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3622-f864b6432fe5006dad6f7aa32aac324599fe64b4dc40a5e5dd3ae4191c676a3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>3.0 T</topic><topic>ADT</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgen Receptor Antagonists - therapeutic use</topic><topic>Anilides - therapeutic use</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Contrast Media</topic><topic>DCE MRI</topic><topic>Diffusion Magnetic Resonance Imaging - methods</topic><topic>DW MRI</topic><topic>Feasibility Studies</topic><topic>Goserelin - therapeutic use</topic><topic>Humans</topic><topic>Imaging, Three-Dimensional</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nitriles - therapeutic use</topic><topic>Organometallic Compounds</topic><topic>prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Tosyl Compounds - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barrett, T.</creatorcontrib><creatorcontrib>Gill, A. B.</creatorcontrib><creatorcontrib>Kataoka, M. Y.</creatorcontrib><creatorcontrib>Priest, A. N.</creatorcontrib><creatorcontrib>Joubert, I.</creatorcontrib><creatorcontrib>McLean, M. A.</creatorcontrib><creatorcontrib>Graves, M. J.</creatorcontrib><creatorcontrib>Stearn, S.</creatorcontrib><creatorcontrib>Lomas, D. J.</creatorcontrib><creatorcontrib>Griffiths, J. R.</creatorcontrib><creatorcontrib>Neal, D.</creatorcontrib><creatorcontrib>Gnanapragasam, V. J.</creatorcontrib><creatorcontrib>Sala, E.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Magnetic resonance in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barrett, T.</au><au>Gill, A. B.</au><au>Kataoka, M. Y.</au><au>Priest, A. N.</au><au>Joubert, I.</au><au>McLean, M. A.</au><au>Graves, M. J.</au><au>Stearn, S.</au><au>Lomas, D. J.</au><au>Griffiths, J. R.</au><au>Neal, D.</au><au>Gnanapragasam, V. J.</au><au>Sala, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study</atitle><jtitle>Magnetic resonance in medicine</jtitle><addtitle>Magn. Reson. Med</addtitle><date>2012-03</date><risdate>2012</risdate><volume>67</volume><issue>3</issue><spage>778</spage><epage>785</epage><pages>778-785</pages><issn>0740-3194</issn><eissn>1522-2594</eissn><abstract>Androgen deprivation therapy (ADT) is a key primary treatment for advanced and metastatic prostate cancer and is an important neoadjuvant before radiotherapy. We evaluated 3.0 T dynamic contrast‐enhanced MRI and diffusion‐weighted (DW) MRI in monitoring ADT response. Twenty‐three consecutive patients with prostate cancer treated by primary ADT were included. Imaging was performed at baseline and 3 months posttreatment with ADT. After 3 months therapy there was a significant reduction in all dynamic contrast‐enhanced MRI parameters measured in tumor regions of interest (Ktrans, kep, vp, IAUGC‐90); P &lt; 0.001. Areas of normal‐appearing peripheral zone showed no significant change; P = 0.285–0.879. Post‐ADT, there was no significant change in apparent diffusion coefficient values in tumors, whilst apparent diffusion coefficient values significantly decreased in areas of normal‐appearing peripheral zone, from 1.786 × 10−3 mm2/s to 1.561 × 10−3 mm2/s; P = 0.007. As expected the median Prostate‐Specific Antigen (PSA) significantly reduced from 30 ng/mL to 1.5 ng/mL posttreatment, and median prostate volume dropped from 47.6 cm3 to 24.9 cm3; P &lt; 0.001. These results suggest that dynamic contrast‐enhanced MRI and diffusion‐weighted MRI offer different information but that both could prove useful adjuncts to the anatomical information provided by T2‐weighted imaging. dynamic contrast‐enhanced as a marker of angiogenesis may help demonstrate ADT resistance and diffusion‐weighted imaging may be more accurate in determining presence of tumor cell death versus residual tumor. Magn Reson Med, 2012. © 2011 Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>22135228</pmid><doi>10.1002/mrm.23062</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0740-3194
ispartof Magnetic resonance in medicine, 2012-03, Vol.67 (3), p.778-785
issn 0740-3194
1522-2594
language eng
recordid cdi_proquest_miscellaneous_922497264
source Wiley-Blackwell Open Access Backfiles; MEDLINE; Wiley Blackwell Single Titles
subjects 3.0 T
ADT
Aged
Aged, 80 and over
Androgen Receptor Antagonists - therapeutic use
Anilides - therapeutic use
Antineoplastic Agents, Hormonal - therapeutic use
Contrast Media
DCE MRI
Diffusion Magnetic Resonance Imaging - methods
DW MRI
Feasibility Studies
Goserelin - therapeutic use
Humans
Imaging, Three-Dimensional
Male
Middle Aged
Nitriles - therapeutic use
Organometallic Compounds
prostate cancer
Prostatic Neoplasms - drug therapy
Tosyl Compounds - therapeutic use
Treatment Outcome
title DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T05%3A14%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DCE%20and%20DW%20MRI%20in%20monitoring%20response%20to%20androgen%20deprivation%20therapy%20in%20patients%20with%20prostate%20cancer:%20A%20feasibility%20study&rft.jtitle=Magnetic%20resonance%20in%20medicine&rft.au=Barrett,%20T.&rft.date=2012-03&rft.volume=67&rft.issue=3&rft.spage=778&rft.epage=785&rft.pages=778-785&rft.issn=0740-3194&rft.eissn=1522-2594&rft_id=info:doi/10.1002/mrm.23062&rft_dat=%3Cproquest_cross%3E922497264%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=922497264&rft_id=info:pmid/22135228&rfr_iscdi=true